ASND

Insider Trades

Name	Value	Action	Price	Current Price
Smith Scott ThomasEVP & Chief Financial Officer $22k100 shares BuyJun 2, 2026 $219.00 --
Smith Scott ThomasEVP & Chief Financial Officer $56k250 shares BuyMay 29, 2026 $223.32 --
Bienaime Jean JacquesDirector $45k200 shares BuyMay 29, 2026 $223.76 --
Bienaime Jean JacquesDirector $44k200 shares BuyMay 29, 2026 $222.30 --
Bienaime Jean JacquesDirector $22k100 shares BuyMay 29, 2026 $223.50 --
Bienaime Jean JacquesDirector $48k200 shares BuyMay 26, 2026 $239.37 --

News

globenewswire.comPhase 3 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH Through Week 182 in Adults with Hypoparathyroidismglobenewswire.comJun 13

seekingalpha.comTouchstone Mid Cap Growth Fund Q1 2026 Portfolio Reviewseekingalpha.comJun 12

globenewswire.com5-Year Phase 2 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH in Adults with Hypoparathyroidismglobenewswire.comJun 11

globenewswire.comAscendis to Showcase Advances in Treatment of Rare Endocrine Diseases at ENDO 2026globenewswire.comJun 8

seekingalpha.comAscendis Pharma: Rare Endocrine Compounder Entering Growth Phase (Initiating Buy)seekingalpha.comMay 28

Trade ASND

About Ascendis Pharma A/S

Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing therapeutic solutions for critical medical conditions that currently lack effective treatments. Its commercialized offering is SKYTROFA, a therapy prescribed for individuals suffering from growth hormone deficiency (GHD). The company boasts a robust development pipeline, featuring several TransCon-branded candidates. These include TransCon Growth Hormone (hGH), which is being progressed for pediatric GHD patients in Japan and for adults with GHD. Also under development are TransCon parathyroid hormone for adults with hypoparathyroidism, and TransCon CNP, aimed at treating pediatric achondroplasia. Further expanding its innovative portfolio, Ascendis is also developing a TransCon toll-like receptor (TLR) 7/8 agonist for intratumoral administration, alongside TransCon IL-2 ß/g, designed for systemic delivery. Founded in 2006, this enterprise maintains its corporate headquarters in Hellerup, Denmark.

CEO: Jan Moller Mikkelsen
IPO Date: Jan 28, 2015

Market Data

Open: $220.44
High: $222.55
Low: $209.56
Volume: 550.6K
52W High: $250.74
52W Low: $160.86

Valuation

Market Cap: $13B
Enterprise Value: $12B

Financials

Free Cash Flow: $44M
Revenue: $692M
Net Income: $-219M
Cash: $616M
Debt: $871M

Events

EarningsAug 6

EPS est. 1.29